Market Analysis: Global Hypogonadism Drug Market
Hypogonadism drug market is rising gradually with a substantial CAGR in the forecast period of 2019-2026. Growing number hypogonadism population and robust product pipeline are the key drivers for market growth.
Market Definition: Global Hypogonadism Drug Market
Hypogonadism is a rare endocrine disorder characterized by insufficient production of testosterone hormone due to failure of testicles. This hormone is essential for functioning of sexual characteristics. The person with hypogonadism may experience weakness, loss of libido, infertility and osteoporosis.
According to the article published in Clarus Therapeutics, it was estimated that over 7.00 million testosterone replacement related drug prescriptions were prescribed by physician. Growing population of hypogonadism and robust pipeline for development of newer therapies are the key factors for market growth.
Get More Insights About Global Hypogonadism Drug Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hypogonadism-drug-market
Market Drivers
• Increase in prevalence rate of hypogonadism worldwide acts as a driver for the market
• Increase in the rate of research and development initiatives is driving the market
• Rising awareness about hypogonadism therapy and technological advancement is driving the market growth
• Ongoing clinical trials is being carried out by many pharmaceuticals companies which acts as a driver for the market
Market Restraints
• Effective treatment is either unavailable or unaffordable
• Patent expiry of major drugs and introduction of generic drugs of branded version is expected to restrain the growth if the market
• Inadequate knowledge about hypogonadism in some developing countries
Segmentation: Global Hypogonadism Drug Market
By Type
• Hypergonadotropic Hypogonadism
• Hypogonadotropic Hypogonadism
By Therapy Type
• Testosterone Replacement Therapy
• Steroid Replacement Therapy
By Treatment
• Medication
• Hormone therapy
• Surgery
By Mechanism of Action Type
• Steroidal androgens
o Testosterone
o Methyltestosterone
• Gonadotropins
o Chorionic Gonadotropin
o Follicle Stimulating Hormone
By Route of administration
• Oral
• Injectable
• Topical
By End Users
• Hospitals
• Homecare
• Specialty Clinics
• Others
By Geography
• North America
o U.S.
o Canada
o Mexico
• South America
o Brazil
o Argentina
o Rest of South America
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Russia
o Turkey
o Belgium
o Netherlands
o Switzerland
o Rest of Europe
• Asia-Pacific
o Japan
o China
o South Korea
o India
o Australia
o Singapore
o Thailand
o Malaysia
o Indonesia
o Philippines
o Rest of Asia Pacific
• Middle East & Africa
o South Africa
o Egypt
o Saudi Arabia
o United Arab Emirates
o Israel
o Rest of Middle East & Africa
Know more about this report https://www.databridgemarketresearch.com/reports/global-hypogonadism-drug-market
Key Developments in the Market:
• In March 2019, Clarus Therapeutics received the FDA approval for Jatenzo (testosterone undecanoate), an oral testosterone replacement therapy for the treatment of primary hypogonadism and hypogonadotropic hypogonadism in men. This approval represents the first oral treatment option for hypogonadism in men.
• In October 2018, Antares Pharma received the FDA approval for Xyosted (testosterone enanthate) Injection, a testosterone replacement therapy for the treatment of primary hypogonadism and hypogonadotropic hypogonadism in men. The FDA approval of Xyosted expanded the company’s branded portfolio in therapeutic area of endocrinology.
Competitive Analysis:
Global hypogonadism drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global hypogonadism market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Get Access Report @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-hypogonadism-drug-market
Key Market Players:
Few of the major competitors currently working in the global hypogonadism drug market are AbbVie Inc., ALLERGAN, AstraZeneca, Bayer AG., Eli Lilly and Company, Clarus Therapeutics, Endo Pharmaceuticals Inc, Merck & Co., Inc., Ferring B.V., Richter Gedeon Vegyeszeti Gyar Nyrt, IBSA Institut Biochimque SA, Laboratoires Genevrier., Teva Pharmaceutical Industries Ltd, Lipocine Inc., Antares Pharma, Pfizer Inc., Aytu BioScience, Inc., Diurnal, HYUNDAIPHARM. Co Ltd., Perrigo Company plc, Bio-Techne and many others.
Primary Respondents
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technical Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Request for Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-hypogonadism-drug-market
Browse Trending Related Reports @
• Hallucinations and Delusions Treatment Market
• Carcinoid Syndrome Drug Market
• Meniere's Disease Drug Market
• Pyelonephritis Treatment Market
• Rosacea Treatment Market
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]